Galt Pharmaceuticals Expands Pain Management Portfolio

tolectinds logo

Galt Pharmaceuticals Expands Pain Management Portfolio with Tolectin DS® (Tolmetin Sodium 400mg Capsules)

Scott Chappell
Scott Chappell

Galt Pharmaceuticals Director of Medical Affairs

Galt Pharmaceuticals proudly announces the introduction of Tolectin DS® (Tolmetin Sodium 400mg Capsules), to it’s growing non-opioid pain product portfolio.

ATLANTA, GEORGIA, USA, May 9, 2024 /EINPresswire.com/ — Galt Pharmaceuticals, a pioneer in developing non-opioid pain management solutions, is proud to announce the introduction of Tolectin DS to its product portfolio. This launch underscores the company’s unwavering commitment to revitalizing safe, effective, non-controlled pain treatments that have been overshadowed by opioid therapies.

Barry Patel, Pharm.D., CEO and Co-Founder of Galt, expressed enthusiasm about the addition, stating, “We are delighted to enhance our portfolio with Tolectin DS, a product known for its distinct clinical benefits. It’s crucial to revisit and promote safe, proven options for pain management that have been neglected due to the widespread marketing of opioids. Our commitment remains strong in reintroducing trusted therapies to the market.”

“It’s crucial to revisit and promote safe, proven options for pain management that have been neglected due to the widespread marketing of opioids.”
— Barry Patel, Pharm.D., CEO and Co-Founder of Galt Pharmaceuticals

Tolectin DS is an FDA-approved Non-Steroidal Anti-Inflammatory Drug (NSAID) formulated to address pain associated with osteoarthritis, rheumatoid arthritis, and juvenile rheumatoid arthritis. Suitable for both acute flare-ups and long-term management, Tolectin DS achieves peak plasma concentration within 30-60 minutes, offering prompt and reliable relief.

Adding to the discourse, Wade Smith, Pharm.D., Chairman and Co-Founder of Galt, noted, “Following the success of our musculoskeletal pain reliever Norgesic, Tolectin DS will further enrich our offerings by targeting bone and joint pain, thereby providing healthcare professionals with options to manage either muscle or bone pain effectively and safely.”

Galt will introduce Tolectin DS through its innovative pharma franchise model (Galt Phranchise Systems) and partnerships with Independent Community Pharmacies to enhance distribution and accessibility. Adam McCown, Pharm.D., owner of Medmetrics Pharmacy in Arizona and a Galt franchisee since 2018, remarked, “Our partnership with Galt has been instrumental in expanding our business. The addition of Tolectin DS will further accelerate our growth while enhancing our capability to meet the evolving needs of our customers.”

For more information about Tolectin DS or to schedule an interview, please contact Tucker Bedingfield at 855-965-2783

About Galt Pharmaceuticals
Based in Atlanta, GA, Galt Pharmaceuticals is a unique pharmaceutical company that develops and commercializes prescription medications that help satisfy the unmet clinical needs of many patient types. Galt leverages business intelligence to identify, develop and bring high-value pharmaceutical products to market through distinctive approaches which include partnerships with independent community pharmacies and entrepreneurs within its franchise network.www.galtrx.com

About Galt Phranchise Systems
Galt Phranchise™ Systems (GPS) is the first and only franchisor to partner with a pharmaceutical company that allows an entrepreneur or business entity to market and promote pharmaceutical and health-related products in local markets. www.galtps.com

About Tolectin DS (Tolmetin Sodium)
Tolmetin Sodium is an FDA-approved Non-Steroidal Anti-Inflammatory Drug (NSAID) indicated to treat pain associated with osteoarthritis, rheumatoid arthritis, and juvenile rheumatoid arthritis. Tolmetin may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke which can be fatal. Tolmetin may also cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. Healthcare professionals and patients should report any adverse events associated with Tolectin to the FDA’s MedWatch program at 1-800-FDA-1088 or www.fda.gov/medwatch.

Tolectin DS is a registered mark of Galt Pharmaceuticals.
Tucker Bedingfield
Galt Pharmaceuticals
+1 855-965-2783
email us here
Visit us on social media:
LinkedIn
YouTube

Galt Pharmaceuticals Acquires Oravig® (Miconazole Buccal Tablets 50mg) from Fortovia Therapeutics

Galt Pharmaceuticals Acquires Oravig® (Miconazole Buccal Tablets 50mg) from Fortovia Therapeutics

Scott Chappell
Scott Chappell

Galt Pharmaceuticals Director of Medical Affairs

ATLANTA–(BUSINESS WIRE)–Galt Pharmaceuticals announced the acquisition of a specialty branded product from Fortovia Therapeutics. Effective December 2, 2020, Galt added Oravig®, the first and only orally-dissolving buccal tablet for oral thrush, to its growing portfolio of pharmaceutical assets.

“We are thrilled to add a branded product with distinctive clinical benefits to our growing product portfolio,” stated Barry Patel, CEO and co-founder of Galt. “We are committed to offering unique products that support unmet clinical needs to improve patients’ quality of life.”

Oral thrush is an infection of the mouth caused by the Candida fungus, also known as yeast. The condition can affect people of all ages including older adults and those with weakened immune systems.

The deal represents a large market opportunity for the Atlanta-based pharmaceutical company. Of the approximately 28 million total prescriptions currently written, filled and dispensed for oral thrush annually in the U.S., more than 22 million are filled for oncology and primary care patients, according to IQVIA Health.

Wade Smith, PharmD, chair and co-founder of Galt added, “Oravig is a specialty product that fits nicely in our phranchise distribution model. It is the third product in our portfolio in as many years. We look forward to supplying Oravig to our phranchisees – just as we have Doral and Orphengesic Forte – both of which achieved record sales in 2020.”

Galt will launch Oravig in Q1 2021 through its unique phranchise sales and distribution model that leverages collaboration with independent pharmacies.

Visit www.Oravig.com for important safety information and full prescribing information.

About Galt Pharmaceuticals

Galt Pharmaceuticals has found a better way to enhance the quality of life of patients with products that answer unmet clinical needs, while creating life-changing opportunities for entrepreneurs, our employees and the individuals within the communities we serve.

Galt is the first and only company to create a unique pharmaceutical franchise or “Phranchise” concept that moves product representation away from corporate headquarters into local communities. Phranchises provide education to local healthcare providers while Galt manages functions such as drug research, regulatory approval, compliance and supply chain.

Learn more at www.GaltRX.com.

About Oravig

Oravig is the first and only muco-adhesive buccal tablet formulation of miconazole approved to treat oropharyngeal candidiasis (OPC), also known as oral thrush, in adult patients in the United States.

Do not use Oravig if there is a known or suspected hypersensitivity to any of its ingredients. Allergic reactions, including anaphylactic reactions and hypersensitivity, have been reported with the administration of miconazole products, including Oravig. Discontinue Oravig immediately at the first sign of hypersensitivity.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see Important Safety Information and Full Prescribing Information for more details.

 

Contacts

Christy Rosell, 404.409.7759
christy@clearwingcommunications.com

 

Opioid-free Pain Med Orphengesic Forte by Galt Pharmaceuticals Approved by FDA

Opioid-free Pain Med Orphengesic Forte by Galt Pharmaceuticals Approved by FDA

Scott Chappell
Scott Chappell

Galt Pharmaceuticals Director of Medical Affairs

ATLANTA–(BUSINESS WIRE)–Pharmaceutical innovator Galt Pharmaceuticals announced a new drug approval to offer a non-opioid, non-controlled, non-addictive alternative for healthcare providers to manage patients suffering from pain. On July 8, 2020 the U.S. Food and Drug Administration approved the company’s Supplemental Abbreviated New Drug Application for Orphengesic Forte, over two months ahead of the scheduled goal date.

“This is a big win in the fight against the U.S. opioid epidemic and the FDA’s swift early action confirms the seriousness of the issue,” said CEO and co-founder Barry Patel, Pharm.D. “Orphengesic Forte is a proven safer pain management alternative healthcare providers can consider before prescribing an opioid.”

Orphengesic Forte is indicated for the relief of mild to moderate pain of acute musculoskeletal disorders, paired with rest, physical therapy and other measures.

“The medical community is in great need of alternative therapeutic options to treat pain and Orphengesic Forte helps to meet that need because pain is very personal,” said Tapan Daftari, M.D., an orthopedic surgeon with Resurgens Orthopedics.

The Centers for Disease Control & Prevention reports 20% of U.S. adults are affected by chronic pain – one of the most common reasons adults seek medical care.

“Management of pain in the United States is a significant issue impacting quality of life for millions of adults,” said Galt Chairman and Co-Founder Wade Smith, Pharm.D. “Patients deserve more options from the best health care system in the world and that’s why we’re committed to expanding our portfolio with more pain medications in coming years.”

About Galt Pharmaceuticals

Galt Pharmaceuticals has found a better way to enhance the quality of life of patients with products that answer unmet clinical needs, while creating life-changing opportunities for entrepreneurs, our employees and the individuals within the communities we serve.

Galt is the first and only pharmaceutical company to create a unique pharmaceutical franchise or “Phranchise” concept that moves product representation away from corporate headquarters into local communities. Phranchises provide education to local healthcare providers while Galt manages functions such as drug research, regulatory approval, compliance and supply chain.

Learn more at www.GaltRX.com.

About Orphengesic Forte

INDICATIONS AND USAGE

Orphengesic Forte (Orphenadrine Citrate, Aspirin and Caffeine 50 mg/ 770 mg/60 mg) Tablets are indicated in:

1. Symptomatic relief of mild to moderate pain of acute musculoskeletal disorders.

2. The orphenadrine component is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions.

The mode of action of orphenadrine has not been clearly identified, but may be related to its analgesic properties. Orphengesic Forte Tablets do not directly relax tense muscles in man.

IMPORTANT SAFETY INFORMATION (ISI)

Contraindications

Orphengesic Forte is contraindicated in patients with glaucoma, pyloric or duodenal obstruction, achalasia, prostatic hypertrophy, obstructions at the bladder neck, myasthenia gravis, hypersensitivity to the drug, and known sensitivities to aspirin or caffeine.

Warnings and Precautions

  • Orphengesic Forte is not recommended in patients with chicken pox, influenza, or flu symptoms due to the possible development of Reye’s Syndrome. Reye’s Syndrome is possibly associated with the use of aspirin.
  • Patients should be cautioned on possible impairment of the ability to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle.
  • Aspirin should be used with extreme caution in the presence of peptic ulcers and coagulation.
  • Safety of use of Orphengesic Forte in pregnancy, during lactation, or in the child-bearing age has not been established; the potential benefits should be weighed against the possible hazard to mother and child.
  • The safe and effective use in children has not been established; Usage in children under 12 is not recommended.
  • Confusion, anxiety, and tremors have been reported with concomitant propoxyphene and orphenadrine.
  • Safety of continuous long term therapy with Orphengesic Forte has not been established; If prescribed for prolonged use, periodic monitoring of blood, urine, and liver function values is recommended.

Adverse Reactions

The side effects of Orphengesic Forte are those seen with aspirin and caffeine or those usually associated with mild anti-cholinergic agents. These may include tachycardia, palpitation, urinary hesitancy or retention, dry mouth, blurred vision, dilation of the pupil, increased intraocular tension, weakness, nausea, vomiting, headache, dizziness, constipation, and drowsiness.

For more safety information and the complete list of adverse reactions, please see the Full Prescribing Information for Orphengesic Forte.

Contacts

Christy Rosell, 404.409.7759
christy@clearwingcommunications.com